Eat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities

November 2, 2026 updated by: City of Hope Medical Center

Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Program

This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.

II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.

III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.

OUTLINE:

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Study Type

Interventional

Enrollment (Actual)

347

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Duarte, California, United States, 91010
        • City of Hope Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Agrees to group consent at week 1
  • Age over 18
  • Able to speak and understand English and/or Spanish

Exclusion Criteria:

  • Don't agree to group consent at week 1
  • Age younger than 18
  • Not able to speak and understand English and/or Spanish
  • Can't participate in physical activity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supportive care (EML program)

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Ancillary studies

Attend EML program sessions

Other Names:
  • Behavior Conditioning Therapy
  • Behavior Modification
  • Behavior or Life Style Modifications
  • Behavior Therapy
  • Behavioral Interventions
  • Behavioral Modification
  • Behavioral Therapy
  • Behavioral Treatment
  • Behavioral Treatments

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12
Time Frame: Baseline and week 12

Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree).

Baseline and week 12
Changes in behavior as measured by questionnaires from baseline to week 12
Time Frame: Baseline and week 12

Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more".

Baseline and week 12
Changes in height from baseline to week 12
Time Frame: Baseline to 12 weeks

Height measured in meters

Baseline to 12 weeks
Changes in weight from baseline to week 12
Time Frame: Baseline to 12 weeks

Weight measured in Kilograms

Baseline to 12 weeks
Changes in waist circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Hip circumference measured in centimeters

Baseline to 12 weeks
Changes in chest circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Chest circumference measured in centimeters

Baseline to 12 weeks
Changes in right upper arm circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Right upper arm circumference measured in centimeters

Baseline to 12 weeks
Changes in left upper arm circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Left upper arm circumference measured in centimeters

Baseline to 12 weeks
Changes in right upper thigh circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Right upper thigh circumference measured in centimeters

Baseline to 12 weeks
Changes in left upper thigh circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Left upper thigh circumference measured in centimeters

Baseline to 12 weeks
Changes in body fat percentage from baseline to week 12
Time Frame: Baseline to 12 weeks

Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage.

Baseline to 12 weeks
Changes in systolic blood pressure from baseline to week 12
Time Frame: Baseline to 12 weeks

Systolic blood pressure measured in mmHG

Baseline to 12 weeks
Changes in diastolic blood pressure from baseline to week 12
Time Frame: Baseline to 12 weeks

Diastolic blood pressure measured in mmHG

Baseline to 12 weeks
Changes in hip circumference from baseline to week 12
Time Frame: Baseline to 12 weeks

Hip circumference measured in centimeters

Baseline to 12 weeks
Changes in biomarkers
Time Frame: Baseline to 12 weeks

Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines.

Baseline to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Victoria L Seewaldt, City of Hope Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2018

Primary Completion (Estimated)

October 11, 2027

Study Completion (Estimated)

October 11, 2027

Study Registration Dates

First Submitted

March 24, 2022

First Submitted That Met QC Criteria

June 8, 2022

First Posted (Actual)

June 10, 2022

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 17410
  • P30CA033572 (U.S. NIH Grant/Contract)
  • 17410 (Other Identifier: City of Hope Comprehensive Cancer Center)
  • NCI-2022-00180 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.